Literature DB >> 25917718

Economic evaluation of Chagas disease screening in Spain.

Iñaki Imaz-Iglesia1, Lucía García-San Miguel2, L Eduardo Ayala-Morillas3, Lidia García-Pérez4, Jesús González-Enríquez5, Teresa Blasco-Hernández6, María Belén Martín-Águeda7, Antonio Sarría-Santamera8.   

Abstract

Although Spain is the European country with the highest Chagas disease burden, the country does not have a national control program of the disease. The purpose of this study is to evaluate the efficiency of several strategies for Chagas disease screening among Latin American residents living in Spain. The following screening strategies were evaluated: (1) non-screening; (2) screening of the Latin American pregnant women and their newborns; (3) screening also the relatives of the positive pregnant women; (4) screening also the relatives of the negative pregnant women. A cost-utility analysis was carried out to compare the four strategies from two perspectives, the societal and the Spanish National Health System (SNHS). A decision tree representing the clinical evolution of Chagas disease throughout patient's life was built. The strategies were compared through the incremental cost-utility ratio, using euros as cost measurement and quality-adjusted life years as utility measurement. A sensitivity analysis was performed to test the model parameters and their influence on the results. We found the "Non-screening" as the most expensive and less effective of the evaluated strategies, from both the societal and the SNHS perspectives. Among the screening evaluated strategies the most efficient was, from both perspectives, to extent the antenatal screening of the Latin American pregnant women and their newborns up to the relatives of the positive women. Several parameters influenced significantly on the sensitivity analyses, particularly the chronic treatment efficacy or the prevalence of Chagas disease. In conclusion, for the general Latin American immigrants living in Spain the most efficient would be to screen the Latin American mothers, their newborns and the close relatives of the mothers with a positive serology. However for higher prevalence immigrant population the most efficient intervention would be to extend the program to the close relatives of the negative mothers.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chagas disease; Costs and costs analysis; Screening; Spain

Mesh:

Substances:

Year:  2015        PMID: 25917718     DOI: 10.1016/j.actatropica.2015.04.014

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  15 in total

1.  Serological Diagnosis of Chronic Chagas Disease: Is It Time for a Change?

Authors:  Alba Abras; Montserrat Gállego; Teresa Llovet; Silvia Tebar; Mercedes Herrero; Pere Berenguer; Cristina Ballart; Carmen Martí; Carmen Muñoz
Journal:  J Clin Microbiol       Date:  2016-04-06       Impact factor: 5.948

Review 2.  Worldwide Control and Management of Chagas Disease in a New Era of Globalization: a Close Look at Congenital Trypanosoma cruzi Infection.

Authors:  Carmen Muñoz; Montserrat Gállego; Alba Abras; Cristina Ballart; Anna Fernández-Arévalo; María-Jesús Pinazo; Joaquim Gascón
Journal:  Clin Microbiol Rev       Date:  2022-03-03       Impact factor: 50.129

3.  Chagas Disease Knowledge and Risk Behaviors of the Homeless Population in Houston, TX.

Authors:  Alexandra Ingber; Melissa N Garcia; Juan Leon; Kristy O Murray
Journal:  J Racial Ethn Health Disparities       Date:  2017-05-31

Review 4.  A global systematic review of Chagas disease prevalence among migrants.

Authors:  Erin E Conners; Joseph M Vinetz; John R Weeks; Kimberly C Brouwer
Journal:  Acta Trop       Date:  2016-01-08       Impact factor: 3.112

Review 5.  Economic evaluations addressing diagnosis and treatment strategies for neglected tropical diseases: an overview.

Authors:  Tália Machado de Assis; Ana Rabello; Gláucia Cota
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2021-05-24       Impact factor: 1.846

6.  Introducing automation to the molecular diagnosis of Trypanosoma cruzi infection: A comparative study of sample treatments, DNA extraction methods and real-time PCR assays.

Authors:  Alba Abras; Cristina Ballart; Teresa Llovet; Carme Roig; Cristina Gutiérrez; Silvia Tebar; Pere Berenguer; María-Jesús Pinazo; Elizabeth Posada; Joaquim Gascón; Alejandro G Schijman; Montserrat Gállego; Carmen Muñoz
Journal:  PLoS One       Date:  2018-04-17       Impact factor: 3.240

7.  Chagas screening and treatment among Bolivians living in Madrid, Spain: The need for an official protocol.

Authors:  María Romay-Barja; Teresa Boquete; Obdulia Martinez; Marlene González; Débora Álvarez-Del Arco; Agustín Benito; Teresa Blasco-Hernández
Journal:  PLoS One       Date:  2019-03-08       Impact factor: 3.240

8.  Prevalence of Chagas disease in Colombia: A systematic review and meta-analysis.

Authors:  Mario J Olivera; Johana A Fory; Julián F Porras; Giancarlo Buitrago
Journal:  PLoS One       Date:  2019-01-07       Impact factor: 3.240

9.  Chagas Disease Infection among Migrants at the Mexico/Guatemala Border.

Authors:  Erin E Conners; Teresa López Ordoñez; Celia Cordon-Rosales; Carmen Fernández Casanueva; Sonia Morales Miranda; Kimberly C Brouwer
Journal:  Am J Trop Med Hyg       Date:  2017-10-10       Impact factor: 2.345

10.  Experiences with Diagnosis and Treatment of Chagas Disease at a United States Teaching Hospital-Clinical Features of Patients with Positive Screening Serologic Testing.

Authors:  Peter Hyson; Lilian Vargas Barahona; Laura C Pedraza-Arévalo; Jonathan Schultz; Luisa Mestroni; Maria da Consolação Moreira; Matthew Taylor; Carlos Franco-Paredes; Esther Benamu; Poornima Ramanan; Anis Rassi; Kellie Hawkins; Andrés F Henao-Martínez
Journal:  Trop Med Infect Dis       Date:  2021-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.